# Anaconda Biomed

> Neurovascular medtech company that closed a $56 million financing to support its pivotal thrombectomy-catheter study.

## Why it is interesting

A material clinical-stage medtech financing with primary-source disclosure and low-difficulty brand search.

## Profile

- **Latest funding:** Growth financing — $56M (September 23, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $56M
- **Stage:** growth
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-09-30
- **Latest funding investors:** Omega Funds, FOCO, Asabys, Ysios Capital, CDTI

## Key facts

- Sep 23, 2026: $56M financing
- Proceeds support the ATHENA pivotal IDE study

## Funding history

- Growth financing · $56M · September 23, 2026
  Source: https://anaconda.bio/anaconda-biomed-secures-56-million-financing-from-new-and-existing-investors/

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 30, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/anaconda-biomed